Trials / Completed
CompletedNCT00160615
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- UCB Japan Co. Ltd. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam | * Pharmaceutical form: Film-coating tablets * Concentration: 250 mg/ 500 mg * Route of administration: oral use |
Timeline
- Start date
- 2001-09-12
- Primary completion
- 2007-01-17
- Completion
- 2007-01-17
- First posted
- 2005-09-12
- Last updated
- 2019-06-10
- Results posted
- 2019-06-10
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00160615. Inclusion in this directory is not an endorsement.